HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: SAHA (vorinostat, Zolinza) is a patent 19, 20, reversible pan-histone deacetylase (HDAC) inhibitor, which has been approved by the FDA for treatment of cutaneous T-cell lymphoma 21.